MicroRNA regulation of AMPK in nonalcoholic fatty liver disease

참고문헌 (120)

1. Powell, E. E., "Non-alcoholic fatty liver disease", Lancet, 397, pp.2212~2224 (2021)
2. Mitra, S., "Epidemiology of non-alcoholic and alcoholic fatty liver diseases", Transl. Gastroenterol. Hepatol, 5, pp.16~ (2020)
3. Cotter, T. G., "Nonalcoholic Fatty Liver Disease 2020 : The State of the Disease", Gastroenterology, 158, pp.1851~1864 (2020)
4. Tsochatzis, E. A., "Natural history of NAFLD : knowns and unknowns", Nat. Rev. Gastroenterol. Hepatol, 19, pp.151~152 (2022)
5. Samuel, V. T., "Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases", Cell Metab, 27, pp.22~41 (2018)
6. Loomba, R., "Mechanisms and disease consequences of nonalcoholic fatty liver disease", Cell, 184, pp.2537~2564 (2021)
7. Eslam, M., "International Consensus, P. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease", Gastroenterology, 158, pp.1999~2014 (2020)
8. Day, E. A., "AMPK as a Therapeutic Target for Treating Metabolic Diseases", Trends Endocrinol. Metab, 28, pp.545~560 (2017)
9. Smith, B. K., "Treatment of nonalcoholic fatty liver disease : role of AMPK", Am. J. Physiol. Endocrinol. Metab, 311, pp.E730~E740 (2016)
10. 전상민, "Regulation and function of AMPK in physiology and diseases", Experimental and Molecular Medicine, 48, pp.1~13 (2016), 생화학분자생물학회
11. Steinberg, G. R., "New insights into activation and function of the AMPK", Nat. Rev. Mol. Cell Biol, 24, pp.255~272 (2023)
12. Herzig, S, "AMPK: guardian of metabolism and mitochondrial homeostasis", Nat. Rev. Mol. Cell Biol, 19, pp.121~135 (2018)
13. Zhao, P., "An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis", Science, 367, pp.652~660 (2020)
14. Steinberg, G. R., "AMPK in Health and Disease", Physiol. Rev, 89, pp.1025~1078 (2009)
15. Trefts, E, "AMPK: restoring metabolic homeostasis over space and time", Mol. Cell, 81, pp.3677~3690 (2021)
16. Gluais-Dagorn, P., "Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis", Hepatol. Commun, 6, pp.101~119 (2022)
17. Garcia, D., "Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity and NAFLD", Cell Rep, 26, pp.192~208 (2019)
18. Woods, A., "Liver-Specific Activation of AMPK Prevents Steatosis on a High-Fructose Diet", Cell Rep, 18, pp.3043~3051 (2017)
19. 김정목, "AMPK activators: mechanisms of action and physiological activities", Experimental and Molecular Medicine, 48, pp.1~12 (2016), 생화학분자생물학회
20. Steinberg, G. R., "AMP-activated protein kinase : the current landscape for drug development", Nat. Rev. Drug Discov, 18, pp.527~551 (2019)
21. Winter, J., "Many roads to maturity : microRNA biogenesis pathways and their regulation", Nat. Cell Biol, 11, pp.228~234 (2009)
22. Bushati, N., "microRNA functions", Annu. Rev. Cell Dev. Biol, 23, pp.175~205 (2007)
23. Agbu, P., "MicroRNA-mediated regulation of glucose and lipid metabolism", Nat. Rev. Mol. Cell Biol, 22, pp.425~438 (2021)
24. Rottiers, V., "MicroRNAs in metabolism and metabolic disorders", Nat. Rev. Mol. Cell Biol, 13, pp.239~250 (2012)
25. Hanna, J., "The Potential for microRNA Therapeutics and Clinical Research", Front. Genet, 10, pp.478~ (2019)
26. Sun, H., "Obesity-induced miR-802directly targets AMPK and promotes nonalcoholic steatohepatitis in mice", Mol. Metab, 66, pp.101603~ (2022)
27. Hur, W., "Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK", AKT pathway, 2015, pp.64, 265~276
28. Long, J. K., "miR-122 promotes hepatic lipogenesis via inhibiting the LKB1", AMPK pathway by targeting Sirt1 in nonalcoholic fatty liver disease, 2019, pp.25, 26~
29. Yousefi, Z., "microRNA-141 is associated with hepatic steatosis by downregulating the sirtuin1", AMP-activated protein kinase pathway in hepatocytes, 2020, pp.235, 880~890
30. Hu, Y., "miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1induction", JHEP Rep, 2, pp.100093~ (2020)
31. Afinanisa, Q., "AMPK Localization: A Key to Differential Energy Regulation", Int. J. Mol. Sci, 22 (2021)[DOI]
32. Meng, X., "Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5′-Monophosphate(AMP)-activated Protein Kinase alpha1", J. Biol. Chem, 291, pp.10625~10634 (2016)
33. Winder, W. W., "Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise", Am. J. Physiol, 270, pp.E299~E304 (1996)
34. Park, H., "Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise", J. Biol. Chem, 277, pp.32571~32577 (2002)
35. Chen, T., "miR-1224-5p Enhances Hepatic Lipogenesis by Targeting Adenosine Monophosphate-Activated Protein Kinase alpha1 in Male Mice", Endocrinology, 159, pp.2008~2021 (2018)
36. Najafi-Shoushtari, S. H., "MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis", Science, 328, pp.1566~1569 (2010)
37. Rayner, K. J., "MiR-33 contributes to the regulation of cholesterol homeostasis", Science, 328, pp.1570~1573 (2010)
38. Davalos, A., "miR-33a", b contribute to the regulation of fatty acid metabolism and insulin signaling, 2011, pp.108, 9232~9237
39. Mihaylova, M. M, "The AMPK signalling pathway coordinates cell growth, autophagy and metabolism", Nat. Cell Biol, 13, pp.1016~1023 (2011)
40. Ha, J., "AMPK and autophagy in glucose", glycogen metabolism, 2015, pp.46, 46~62
41. Liu, Y. M., "MiR-19a Affects Hepatocyte Autophagy via Regulating lncRNA NBR2 and AMPK", PPARalpha in D-GalN, J. Cell Biochem, pp.2018, 119[DOI]
42. Liu, X., "LncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress", Nat. Cell Biol, 18, pp.431~442 (2016)
43. Simino, L. A. P., "MicroRNA Let-7 targets AMPK and impairs hepatic lipid metabolism in offspring of maternal obese pregnancies", Sci. Rep, 11, pp.8980~ (2021)
44. Kornfeld, J. W., "Obesity-induced overexpression of miR-802 impairs glucose metabolism through silencing of Hnf1b", Nature, 494, pp.111~115 (2013)
45. Seok, S., "Defective FXR-SHP Regulation in Obesity Aberrantly Increases miR-802 Expression, Promoting Insulin Resistance and Fatty Liver", Diabetes, 70, pp.733~744 (2021)
46. Ni, Y., "Therapeutic inhibition of miR-802 protects against obesity through AMPK-mediated regulation of hepatic lipid metabolism", Theranostics, 11, pp.1079~1099 (2021)
47. Zhao, P., "From overnutrition to liver injury : AMP-activated protein kinase in nonalcoholic fatty liver diseases", J. Biol. Chem, 295, pp.12279~12289 (2020)
48. Zhang, T., "MicroRNA-378 promotes hepatic inflammation and fibrosis via modulation of the NF-kappaB-TNFalpha pathway", J. Hepatol, 70, pp.87~96 (2019)
49. Shackelford, D. B, "The LKB1-AMPK pathway: metabolism and growth control in tumour suppression", Nat. Rev. Cancer, 9, pp.563~575 (2009)
50. Lee, C. G., "Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1", Gastroenterology, 142, pp.1206~1217 (2012)
51. Lan, F., "SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMPactivated protein kinase activation", J. Biol. Chem, 283, pp.27628~27635 (2008)
52. Lee, J., "A pathway involving farnesoid X receptor and small heterodimer partner positively regulates hepatic sirtuin 1 levels via microRNA-34a inhibition", J. Biol. Chem, 285, pp.12604~12611 (2010)
53. Hu, L. K., "MicroRNA-506-3p targets SIRT1 and suppresses AMPK pathway activation to promote hepatic steatosis", Exp. Ther. Med, 22, pp.1430~ (2021)
54. Marcelo, K. L., "The Ca(2+)", Calmodulin, Trends Endocrinol. Metab, pp.2016, 27[DOI]
55. Wang, Y. Z., "microRNA-378b regulates ethanol-induced hepatic steatosis by targeting CaMKK2 to mediate lipid metabolism", Bioengineered, 12, pp.12659~12676 (2021)
56. Combs, T. P., "Adiponectin signaling in the liver", Rev. Endocr. Metab. Disord, 15, pp.137~147 (2014)
57. Yoon, M. J., "Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogenactivated protein kinase, and peroxisome proliferator-activated receptor alpha", Diabetes, 55, pp.2562~2570 (2006)
58. Alzahrani, B., "The role of AdipoR1 and AdipoR2 in liver fibrosis", Biochim. Biophys. Acta. Mol. Basis Dis, 1864, pp.700~708 (2018)
59. Yamauchi, T., "Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions", Nat. Med, 13, pp.332~339 (2007)
60. Lustig, Y., "RNA-binding protein PTB and microRNA-221 coregulate AdipoR1translation and adiponectin signaling", Diabetes, 63, pp.433~445 (2014)
61. Wei, G., "miR-320 mediates diabetes amelioration after duodenal-jejunal bypass via targeting adipoR1", Surg. Obes. Relat. Dis, 14, pp.960~971 (2018)
62. Du, H., "MicroRNA-218 targets adiponectin receptor 2 to regulate adiponectin signaling", Mol. Med. Rep, 11, pp.4701~4705 (2015)
63. Wen, F., "MiR-34a regulates mitochondrial content and fat ectopic deposition induced by resistin through the AMPK", PPARalpha pathway in HepG2 cells, 2018, pp.94, 133~145
64. Kim, H. J., "Liver-specific deletion of RORalpha aggravates diet-induced nonalcoholic steatohepatitis by inducing mitochondrial dysfunction", Sci. Rep, 7, pp.16041~ (2017)
65. Kim, E. J., "Retinoic acid receptor-related orphan receptor alpha-induced activation of adenosine monophosphate-activated protein kinase results in attenuation of hepatic steatosis", Hepatology, 55, pp.1379~1388 (2012)
66. Kim, K., "RORalpha controls hepatic lipid homeostasis via negative regulation of PPARgamma transcriptional network", Nat. Commun, 8, pp.162~ (2017)
67. Horii, R., "MicroRNA-10a Impairs Liver Metabolism in Hepatitis C Virus-Related Cirrhosis Through Deregulation of the Circadian Clock Gene Brain and Muscle Aryl Hydrocarbon Receptor Nuclear Translocator-Like 1", Hepatol. Commun, 3, pp.1687~1703 (2019)
68. Yu, Y., "MicroRNA-665-3p exacerbates nonalcoholic fatty liver disease in mice", Bioengineered, 13, pp.2927~2942 (2022)
69. Li, Y., "Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism", Hepatol. Int, 14, pp.1057~1074 (2020)
70. Kim, I. H., "Aging and liver disease", Curr. Opin. Gastroenterol, 31, pp.184~191 (2015)
71. Gong, H., "miR-146a impedes the anti-aging effect of AMPK via NAMPT suppression and NAD(+)", SIRT inactivation, 2022, pp.7, 66~
72. Li, Y., "CD36 plays a negative role in the regulation of lipophagy in hepatocytes through an AMPK-dependent pathway", J. Lipid Res, 60, pp.844~855 (2019)
73. Wang, X., "MicroRNA-20a-5p Ameliorates Nonalcoholic Fatty Liver Disease via Inhibiting the Expression of CD36", Front. Cell Dev. Biol, 8, pp.596329~ (2020)
74. Lin, H. Y., "MicroRNA-29a Suppresses CD36to Ameliorate High Fat Diet-Induced Steatohepatitis and Liver Fibrosis in Mice", Cells, 8 (2019)[DOI]
75. Zhang, Y. J., "microRNA-519d Induces Autophagy and Apoptosis of Human Hepatocellular Carcinoma Cells Through Activation of the AMPK Signaling Pathway via Rab10", Cancer Manag. Res, 12, pp.2589~2602 (2020)
76. Guo, J. C., "microRNA-448 inhibits stemness maintenance and self-renewal of hepatocellular carcinoma stem cells through the MAGEA6-mediated AMPK signaling pathway", J. Cell Physiol, 234, pp.23461~23474 (2019)
77. Chen, Y., "MicroRNA-1271 functions as a potential tumor suppressor in hepatitis B virus-associated hepatocellular carcinoma through the AMPK signaling pathway by binding to CCNA1", J. Cell Physiol, 234, pp.3555~3569 (2019)
78. Marco Tomasetti, "Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy", Experimental and Molecular Medicine, 49, pp.1~11 (2017), 생화학분자생물학회
79. Pan, Y., "Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-induced adipose inflammation", J. Clin. Invest, 129, pp.834~849 (2019)
80. Zhou, Z. W., "Clinical implications of exosome-derived noncoding RNAs in liver", Lab Invest, 102, pp.464~473 (2022)
81. Jiao, Y., "Advances on liver cell-derived exosomes in liver diseases", J. Cell Mol. Med, 25, pp.15~26 (2021)
82. Isaac, R., "Exosomes as mediators of intercellular crosstalk in metabolism", Cell Metab, 33, pp.1744~1762 (2021)
83. Gao, H., "MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH", Cell Metab, 34, pp.978~990 (2022)
84. Chen, L., "Exosomal miR-500 Derived From Lipopolysaccharide-Treated Macrophage Accelerates Liver Fibrosis by Suppressing MFN2", Front. Cell Dev. Biol, 9, pp.716209~ (2021)
85. Fang, Z., "MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease", Int. J. Biol. Sci, 17, pp.1851~1863 (2021)
86. Szabo, G., "Role of MicroRNAs in NAFLD", NASH, 2016, pp.61, 1314~1324
87. Kim, Y. C., "MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice", Hepatology, 71, pp.2118~2134 (2020)
88. Zhang, F., "Obesity-induced overexpression of miR-802 impairs insulin transcription and secretion", Nat. Commun, 11, pp.1822~ (2020)
89. Ding, J., "Effect of miR-34a in regulating steatosis by targeting PPARalpha expression in nonalcoholic fatty liver disease", Sci. Rep, 5, pp.13729~ (2015)
90. Choi, S. E., "Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT", Aging Cell, 12, pp.1062~1072 (2013)
91. Navarro, F., "miR-34 and p53 : New Insights into a Complex Functional Relationship", PLoS One, 10, pp.e0132767~ (2015)
92. Okada, N., "A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression", Genes Dev, 28, pp.438~450 (2014)
93. Chang, T. C., "Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis", Mol. Cell, 26, pp.745~752 (2007)
94. Raver-Shapira, N., "Transcriptional activation of miR-34a contributes to p53-mediated apoptosis", Mol. Cell, 26, pp.731~743 (2007)
95. Slabakova, E., "Alternative mechanisms of miR-34a regulation in cancer", Cell Death Dis, 8, pp.e3100~ (2017)
96. 한혜숙, "Role of CRTC2 in Metabolic Homeostasis: Key Regulator of Whole-Body Energy Metabolism?", Diabetes and Metabolism Journal, 44(4), pp.498~508 (2020), 대한당뇨병학회[DOI]
97. Han, H. S., "Hepatic Crtc2 controls whole body energy metabolism via a miR-34a-Fgf21 axis", Nat. Commun, 8, pp.1878~ (2017)
98. Han, H. S., "A novel role of CRTC2 in promoting nonalcoholic fatty liver disease", Mol. Metab, 55, pp.101402~ (2022)
99. Machado, I. F., "miR-378a : a new emerging microRNA in metabolism", Cell Mol. Life Sci, 77, pp.1947~1958 (2020)
100. Carrer, M., "Control of mitochondrial metabolism and systemic energy homeostasis by microRNAs 378 and 378*", Proc. Natl. Acad. Sci. USA, 109, pp.15330~15335 (2012)
101. Zhang, T., "LXRalpha Promotes Hepatosteatosis in Part Through Activation of MicroRNA-378 Transcription and Inhibition of Ppargc1beta Expression", Hepatology, 69, pp.1488~1503 (2019)
102. Mercer, T. R., "Long non-coding RNAs : insights into functions", Nat. Rev. Genet, 10, pp.155~159 (2009)
103. Bridges, M. C., "LNCcation: lncRNA localization and function", J. Cell Biol, 220 (2021)[DOI]
104. Wu, P., "Ginsenoside Rg3 alleviates septic liver injury by regulating the lncRNA TUG1", miR-200c-3p, J. Inflamm. (Lond), pp.2021, 18[DOI]
105. Guo, B., "LncRNA HOTAIR regulates the lipid accumulation in non-alcoholic fatty liver disease via miR-130b-3p", ROCK1 axis, 2022, pp.90, 110190~
106. Huang, H., "Rho-kinase", AMPK axis regulates hepatic lipogenesis during overnutrition, 2018, pp.128, 5335~5350
107. Fouqueray, P., "Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease : A phase 1b study", Cell Rep. Med, 2, pp.100474~ (2021)
108. Chakraborty, C., "Therapeutic advances of miRNAs : A preclinical and clinical update", J. Adv. Res, 28, pp.127~138 (2021)
109. Momin, M. Y., "The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint", Cells, 10 (2021)[DOI]
110. Sempere, L. F., "microRNA-based diagnostic and therapeutic applications in cancer medicine", Wiley Interdiscip Rev. RNA, 12, pp.e1662~ (2021)
111. Winkle, M., "Noncoding RNA therapeutics-challenges and potential solutions", Nat. Rev. Drug Discov, 20, pp.629~651 (2021)
112. Dufour, J. F., "Combination therapy for non-alcoholic steatohepatitis : rationale, opportunities and challenges", Gut, 69, pp.1877~1884 (2020)
113. Sinakos, E., "Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis", Ann. Gastroenterol, 35, pp.213~225 (2022)
114. Olivier, S., "Promise and challenges for direct small molecule AMPK activators", Biochem. Pharmacol, 153, pp.147~158 (2018)
115. Xu, G., "Hepatic AMP Kinase as a Potential Target for Treating Nonalcoholic Fatty Liver Disease : Evidence from Studies of Natural Products", Curr. Med. Chem, 25, pp.889~907 (2018)
116. Singaravelu, R., "MicroRNA-7 mediates cross-talk between metabolic signaling pathways in the liver", Sci Rep, 8, pp.361~ (2018)
117. Chen, X., "LncRNA NEAT1 promotes hepatic lipid accumulation via regulating miR-146a-5p", ROCK1 in nonalcoholic fatty liver disease, 2019, pp.235, 116829~
118. Chen, J., "miR-1", AMPK-Mediated glucose and lipid metabolism under chronic hypothermia in the liver of freshwater drum, aplodinotus grunniens, 2022, pp.12, 697~
119. Yin, H., "MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1", J Biol Chem, 287, pp.9817~9826 (2012)
120. Jin, X., "Antagonizing circRNA_002581-miR-122-CPEB1 axis alleviates NASH through restoring PTEN-AMPK–mTOR pathway regulated autophagy", Cell Death Dis, 11, pp.123~ (2020)

관련 논문AI추천